Search
Massachusetts Paid Clinical Trials
A listing of 3221 clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1117 - 1128 of 3221
Massachusetts is currently home to 3221 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
The Role of Vitamin K on Knee Osteoarthritis Outcomes
Recruiting
The appropriate form and dosing of vitamin K to benefit relevant outcomes in knee osteoarthritis (OA) are not known. In intervention studies for conditions other than knee OA (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin K1; 1000µg or 500µg daily) or menaquinone-7 (MK-7 or vitamin K2; 300µg daily). However, whether these doses are adequate to increase vitamin K to levels that ameliorate risk of adverse OA outcomes is not known... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/03/2025
Locations: Boston Medical Center, Rheumatology Clinic, Boston, Massachusetts
Conditions: Osteo Arthritis Knee
Sapphire 3 CTO Study
Recruiting
A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device performance of the Sapphire 3 0.85, 1.0 and 1.25mm diameter coronary dilatation catheter in predilatation of Chronic Total Occlusion (CTO) lesions during percutaneous coronary intervention.
One hundred seventy (170) subjects will be enrolled with a target of one hundred fifty-three (153) evaluable subjects by the angiographic core laboratory at up to 15 clinical sites with t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
Recruiting
Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: PSC
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Recruiting
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases.
The goal of this Phase 2a, randomized, double-blind placebo-controlled, multicenter dose-ranging study is to evaluate the use of nasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS).
The primary objectives that this study aims to answer are:
1. To determine the safety and tolerability of 50 μg/dose and 100 μg/dose of foralumab nasa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Secondary Progressive Multiple Sclerosis
TENS Unit for Analgesia During IUD Insertion
Recruiting
Subjects will be screened over the phone or in Tufts GYN clinic for participation in the study. If eligible and interested in participating, written informed consent (and assent if applicable) will be obtained. After informed consent/assent, the patient will be enrolled in the study. The patient will decide if they desire to use TENS unit during IUD insertion appointment and inform the study team. The clinic visit will proceed as normal, with additional study proceedings as follows. The study pe... Read More
Gender:
FEMALE
Ages:
Between 12 years and 50 years
Trial Updated:
06/03/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: IUD, Analgesia, Patient Preference, Pain, Acute
Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis
Recruiting
Osteonecrosis of the femoral head (ONFH) is a debilitating musculoskeletal disease that is characterized by localized death of bone cells and associated cellular elements within the subchondral bone. If it progresses, it results in the collapse of the femoral head (ball part of the hip) giving rise to secondary arthritis. This condition is associated with marked pain and loss of function, often necessitating a joint replacement. Due to the relatively young age of onset of ONFH (often in 20s and... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/03/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Osteonecrosis of the Femoral Head, Avascular Necrosis of the Femoral Head
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/03/2025
Locations: Investigator Site #1077, Burlington, Massachusetts
Conditions: SLE
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Recruiting
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS).
The name of the study drugs involved in this study are:
* Belumosudil (an immunotherapy)
* Fluticasone (an intranasal corticosteroid)
* Azithromycin (an antibiotic)
* Montelukast (a leukotriene receptor antagonist)
* Predn... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
Recruiting
Part A of this trial will evaluate the safety and tolerability of a single unilateral administration of one of two dose levels of AAVAnc80-hOTOF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Gender:
ALL
Ages:
All
Trial Updated:
06/03/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Sensorineural Hearing Loss, Bilateral
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
Recruiting
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
Recruiting
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Gender:
ALL
Ages:
All
Trial Updated:
06/03/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Kidney Transplantation in Highly Sensitized Patients
Access Cannulation Trial II
Recruiting
This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Dialysis; Complications, Vascular Access Complication